about
Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance.The mTOR signalling pathway in human cancerTherapeutic Implications of Targeting AKT Signaling in MelanomaConstitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosisRole of APC and DNA mismatch repair genes in the development of colorectal cancers.Current State of Animal (Mouse) Modeling in Melanoma ResearchTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Melanoma: from mutations to medicineAsymmetrical macromolecular complex formation of lysophosphatidic acid receptor 2 (LPA2) mediates gradient sensing in fibroblasts.Nuclear PTEN levels and G2 progression in melanoma cellsCell cycle gene networks are associated with melanoma prognosisDNA-damaging autoantibodies and cancer: the lupus butterfly theory.Strategies and challenges in eliciting immunity to melanoma.PTEN attenuates PIP3/Akt signaling in the cochlea of the aging CBA/J mouse.Anti-neoplastic efficacy of Haimiding on gastric carcinoma and its mechanismsInduction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1).miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells.Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.Melanoma genetics and the development of rational therapeutics.WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner.Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma.Directed migration of cancer cells guided by the graded texture of the underlying matrix.Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.Personal history of endometriosis and risk of cutaneous melanoma in a large prospective cohort of French womenKLF6 Gene and early melanoma development in a collagen I-rich extracellular environment.Novel somatic mutations to PI3K pathway genes in metastatic melanomaThe antiproliferative response of indole-3-carbinol in human melanoma cells is triggered by an interaction with NEDD4-1 and disruption of wild-type PTEN degradationTargeted therapy for melanoma: a primer.Expression of genes encoding extracellular matrix proteins: a macroarray study.Driver mutations in melanoma: lessons learned from bench-to-bedside studiesGenotyping of cutaneous melanoma.Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistanceUse of human tissue to assess the oncogenic activity of melanoma-associated mutations.Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acidsPI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.RSK1 activation promotes invasion in nodular melanoma.The T-box transcription factor, TBX3, is a key substrate of AKT3 in melanomagenesis.Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosisArsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway.
P2860
Q21093282-11015A58-C5E9-403D-BBB7-B4D4BE4D8938Q24627306-62413EBD-2054-4C8A-B9F7-DB775E3C4A13Q24631438-FF14E806-FAD4-44A4-BCE6-05E4F09CC995Q24791830-8842D407-760E-4E0D-9AB7-B450FCFA30F5Q24806345-4AA560D0-F519-48F6-B78B-F4AF2589798CQ26781652-E1541473-B214-4874-8357-A083B7A01D22Q26782222-37E31759-D1E1-4254-ACD9-B8F3DFB264B3Q27024061-F85F3C51-296C-4CF2-BC0A-23A9B0922550Q27314683-147A48C7-7E2A-4668-B3BE-4CC273BC1577Q28391204-404F7D15-32A5-4470-879E-9D0D6E413ADDQ28482466-C4D2C49C-5207-4D96-974E-99CEE5F31B4BQ30251723-F87A8087-9C6C-48C2-A57C-244C75A980E5Q30435893-FE151637-27DD-4A41-ACE4-8CCAD4CCCDD7Q30475282-A7ACF1A2-8B96-42EB-AAFC-433F92BDBE33Q33198297-74F015C0-2F05-4061-9258-2D2083BDAC49Q33480990-6966255F-B7BB-46AD-87AE-0119D2C20362Q33605016-68E5C791-02D7-4FE1-B12C-D13BB09A830AQ33709560-F371C162-CAF3-42DA-A6AF-ECDF4381034DQ33725172-DC823060-1594-4C9F-84AE-5AA5826152AEQ33726956-66982671-6048-4B66-8FEA-CCDD3B2B376CQ33785885-BF417119-D9B2-4704-9B62-50666D1ECDB4Q33873686-BB5A232E-95FB-4B4B-8DA8-1B944538C0AAQ33918106-62C4414D-4AF8-4DE9-A161-CB08B2020479Q34000333-2E3B4FD4-2102-42DD-99B6-0142B213AFE9Q34007748-B7B2EF87-D4D7-4502-BF27-98875486C48BQ34039690-3A4FDA52-0ED1-4C45-A2C2-C6D19EBAE5FDQ34389570-F5024354-2ABE-4A77-9D0A-CE10D72C9AD7Q34518472-22135513-48C7-4B56-8D93-12578A4F81CAQ34540273-BFCC499D-176B-45DF-A5BB-123BB61F54DDQ34556688-C9639FF1-4DE2-43E3-A65C-46C684650251Q34639532-D1D04CE1-D438-4002-97D0-1BF3FA4AA16CQ34667738-38EBA1CA-399F-47F4-AA3C-F75241AF912AQ34669370-E5D15843-40D9-4FF0-9C9C-E5CA5AE977D4Q34716087-ABE8110E-ED4F-459E-AA13-A7D25ECA245EQ35033761-698E4BC4-5AEC-4996-9361-04C297A6D134Q35060792-BE053A54-2994-4BAD-8AB0-F0FAE87EF142Q35143744-6DE7A639-EEE5-4E7F-BB35-5C435E2FB8B5Q35176448-43945D3B-85C2-4186-B124-1F2FEDBDD54FQ35230726-786C6460-413B-4487-BD25-7B52BBBD9295Q35320386-A8C6A1A0-2613-4C5B-B933-D5ED6531F464
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
PTEN signaling pathways in melanoma.
@ast
PTEN signaling pathways in melanoma.
@en
type
label
PTEN signaling pathways in melanoma.
@ast
PTEN signaling pathways in melanoma.
@en
prefLabel
PTEN signaling pathways in melanoma.
@ast
PTEN signaling pathways in melanoma.
@en
P2093
P356
P1433
P1476
PTEN signaling pathways in melanoma.
@en
P2093
Frank G Haluska
Vikas Goel
P2888
P304
P356
10.1038/SJ.ONC.1206451
P407
P577
2003-05-01T00:00:00Z
P5875
P6179
1038108476